|
CAS
|
9003-11-6
|
|
中文名称
|
泊洛沙姆407
|
|
英文名称
|
Poloxamer 407
|
|
分子式
|
No data available
|
|
外观（性状）
|
White to off-white Solid
|
|
储存条件
|
Powder : 2-8℃, 2 years; In solvent(母液): -20℃, 1 month; -80℃, 6 months
|
|
溶解性
|
Soluble in Water
|
|
MDL
|
MFCD00082049
|
|
EC
|
EINECS 618-355-0
|
|
描述
|
是非离子型表面活性剂,有特殊的反向热胶凝作用,刺激性小,生物相容性好,是一个理想的药物控释材料(It is a non-ionic surfactant with special reverse thermal gelation, low irritation, good biocompatibility, and is an ideal drug controlled release material)
|
|
In Vivo
|
In order to efficiently transfer the Adeno-associated virus (AAV) into the vein graft walls and avoid any potential systemic side effects, we used a local delivery method by using poloxamer-407 (Solarbio, Beijing China) with trypsin as our previously described [14,15,17]. Briefly, after end to end anastomosis of the vein segment to common carotid artery, 30ul AAV6-anti-miR-92a or AAV6-control (Shanghai GeneChem, Co., Ltd. Shanghai, China) fluid was preloaded into 120 μl 25% poloxamer-407 pluronic gel containing 0.25% trypsin at 4?C, and was gently painted around the grafted vein segments.[1]
|
|
数据来源文献
|
[1]. Zhong CM, Li S, Wang XW, Chen D, Jiang ZL, Zhang C, He XJ, Huang C, Jiang YJ, Wu QC. MicroRNA-92a -mediated endothelial to mesenchymal transition controls vein graft neointimal lesion formation. Exp Cell Res. 2021 Jan 1;398(1):112402
|
|
规格
|
500mg 1g
|
|
单位
|
瓶
|
